RBC Keeps MannKind (MNKD) at 'Underperform'; Afrezza Plans in Limbo Until CCO Hired
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
MannKind (MNKD) Continues Squeezing Higher as Shorts Take Notice
March 17, 2016 2:25 PM EDTMannKind Corp. (Masdaq: MNKD) shares are continuing to see a squeeze today and have moved to session highs Thursday afternoon on strong volume.
Short interest was last at 117,258,191 shares, or about 42.7 percent of float, at the end of February. Days-to-cover is 24.7,... More
MannKind (MNKD) Posts Q4 Loss of 66c/Share
March 14, 2016 4:50 PM EDTMannKind (NASDAQ: MNKD) reported Q4 EPS of ($0.66), which may not compare with the analyst estimate of ($0.05).
Sales of Afrezza continued to be lower than expected during the fourth quarter of 2015, culminating in a decision by Sanofi on January 4, 2016 to return the... More
MannKind (MNKD) Appoints New Chief Commercial Officer; COO Martens Resigns
March 14, 2016 4:01 PM EDTMannKind Corporation (Nasdaq: MNKD) announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global... More
